Hepatopulmonary syndrome (HPS) is defined as a clinical triad characterised by an oxygenation defect induced by the presence of pulmonary vasodilation observed in patients with liver disease or portal hypertension ([@B20]). There are no pathognomonic signs or symptoms of HPS, although dyspnoea, platypnoea, peripheral cyanosis, digital clubbing, and spider naevi may be observed ([@B25]. While the pathophysiology of HPS has not been fully clarified, it is known that in portal hypertension, there is an increase in substances produced by the liver that could act on the lungs, thereby promoting vasodilation, with a consequent increase in the arterial alveolar oxygen gradient and hypoxemia ([@B20].

Portal hypertension may also lead to another vascular pulmonary complication, pulmonary arterial hypertension ([@B26]). Its pathophysiology is opposite to HPS, being pulmonary vasoconstriction and elevated pulmonary vascular resistance ([@B25]). Unlike HPS, pulmonary arterial hypertension may be idiopathic or secondary to various conditions besides portal hypertension ([@B26]). The diagnosis of pulmonary arterial hypertension is confirmed by haemodynamic studies, and occurs in 2% to 6% of patients with portal hypertension, including schistosomiasis ([@B19], [@B26]). The prevalence of HPS is lower in patients with non-cirrhotic portal hypertension (8% to 9.7%), than in those with cirrhosis (15% to 17.5%), in whom the presence of HPS is related to a poor prognosis ([@B8], [@B21], [@B17], [@B12], [@B13]).

In Brazil, a leading cause of non-cirrhotic portal hypertension is hepatosplenic schistosomiasis (HSS), which results from chronic infection with *Schistosoma mansoni* ([@B15], [@B18]). When patients with HSS develop cirrhosis due to infection with hepatitis B virus (HBV) or hepatitis C virus (HCV), chronic alcohol consumption, or other causes, their prognosis worsens as a result of greater impairment of liver function, with a possibility of the involvement of other organs or systems ([@B5], [@B2], [@B27]).

In HSS patients, HPS is rarely reported, either because its prognostic implications are not well known, or because HSS patients typically show only mild impairment of their liver function and are therefore not candidates for liver transplantation ([@B14], [@B18]). In addition, it has yet to be determined whether concomitant cirrhosis in HSS patients plays a role in the development of HPS. The objective of this study was to undertake a prospective investigation into the prevalence of HPS in patients with HSS, and to determine whether the occurrence of HPS is influenced by concomitant hepatic cirrhosis.

SUBJECTS AND METHODS
====================

This was a prospective, cross-sectional, hospital-based study, in which all patients diagnosed with HSS and oesophageal varices, with or without concomitant liver cirrhosis, between April 2010 and December 2012 were eligible for inclusion in this study protocol, i.e., screening for HPS. Splenectomised patients and those who had consumed alcohol in the past six months, presented with severe cardiac disease or severe restrictive or obstructive lung disorder observed on spirometry or were receiving antiviral therapy for hepatitis, were excluded.

Each patient was evaluated individually by the same observer. On this occasion, information regarding the period and place of exposure to *S. mansoni* was obtained through the patient's origin and previous addresses, previous treatment with praziquantel (PZQ), previous blood transfusion, alcohol consumption and laboratory diagnosis of infection with HBV and HCV.

The diagnosis of HSS was based on a history of contact with water in an area endemic for *S. mansoni*, together with ultrasound findings of periportal hepatic fibrosis (Symmers' fibrosis) and splenomegaly ([@B24]). The additional diagnosis of liver cirrhosis in patients with HSS was based on clinical findings, liver function test results, and ultrasound findings consistent with a diagnosis of liver cirrhosis (liver surface nodularity, evaluated by ultrasound at the left liver lobe) as well as on liver histology when a biopsy was performed ([@B5], [@B3]). The severity of liver disease was assessed by Child-Pugh criteria (hepatic encephalopathy, ascites, prothrombin time or the international normalised ratio and serum levels of albumin and bilirubin) and the model for end-stage liver disease (MELD) score ([@B6], [@B16]). The severity of previous lung disease was assessed by performing forced spirometry in all patients (Micro Kit; Cosmed, Rome, Italy), and predicted values were based on the reference values for Brazil ([@B23]).

The diagnosis of HPS was based on a widened alveolar-arterial partial pressure oxygen gradient (AaPO~2~) (≥ 15 mmHg or ≥ 20 mmHg for individuals over 64 years of age), with or without arterial hypoxemia (PaO~2~ \< 80 mmHg), and intrapulmonary vascular dilatation (IPVD), as diagnosed by transthoracic contrast-enhanced echocardiography ([@B25]). Patients without HPS were included as controls.

*Procedures for diagnosing HPS*: *transthoracic contrast-enhanced echocardiography* - Echocardiography was performed with an ultrasound system (HDI 1500; Philips Medical Systems, Eindhoven, the Netherlands). With the patient in the lateral decubitus position, we punctured a vein in the arm and inserted a three-way catheter for contrast injection (0.9% saline). The test was considered positive for IPVD if opacification of the left atrium was observed between the fourth and the sixth cardiac cycles, counted from the opacification of the right atrium in the absence of intracardiac communications ([@B28]).

*Arterial blood gas analysis* - Arterial blood samples were obtained through radial artery puncture while the patient was seated, at rest, and breathing ambient air at sea level. Each sample was immediately analysed (GEM 3000; Instrumentation Laboratory, Bedford, MA, USA) to determine the pH, PaO~2~ and arterial carbon dioxide tension (PaCO~2~) values. The AaPO~2~ value was calculated according to the alveolar gas equation ([@B25]).

*Statistical analysis -* Statistical analysis was performed using the Statistical Package for the Social Sciences, version 8.0 (SPSS Inc., Chicago, IL, USA). Continuous variables are expressed as mean ± standard deviation and categorical variables, as absolute and relative frequencies. As measures of association, we used the Student's t-test for continuous variables and the *X* ^*2*^ test, together with Fisher's exact test, when indicated, for categorical variables. The cases without HPS were used as controls. Values of p \< 0.05 were considered statistically significant.

*Ethics -* The study was approved by the Research Ethics Committee of the Federal University of Pernambuco Health Sciences Centre (Protocol no. 396/2010). All participating patients provided written informed consent.

RESULTS
=======

Of the 175 patients diagnosed with HSS and oesophageal varices, 121 completed the study protocol. The study included 68 males (56.2%), and the mean age was 56 ± 12 years. All patients had been exposed to water contaminated by *S. mansoni*; 62 (51.2%) presented a history of treatment with PZQ, and 64 (52.8%) presented with the additional diagnosis of cirrhosis, the most common cause of which was alcohol consumption (43.8%) followed by HCV infection (28.1%) ([Table I](#t1){ref-type="table"}).

TABLE IAge, gender and epidemiological characteristics of 121 patients with hepatosplenic schistosomiasis (HSS) N(%)Age (mean ± standard deviation)55,6 ± 11,50 GenderMale6856.2Female5343.8Exposure to *Schistosoma mansoni* contaminated waterNo00.0Yes121100.0Previous treatment for schistosomiasisNo5948.8Yes6251.2Hemotransfusion historyNo7461.2Yes4738.8Cause of cirrhosi^*\**^Alcohol2843.8HCV1828.1HBV-Alcohol710.9HBV69.4HCV-Alcohol11.6HCV-HBV11.6Cirrhosis through other causes34.6[^2]

Forty-two patients (35%) were diagnosed with HPS. The prevalence of HPS was higher among patients with cirrhosis than among those without cirrhosis (42% vs. 26%, respectively), but the difference was not significant (p = 0.069). The prevalence of HPS was also higher among patients with spider naevi, those classified as Child-Pugh class B or C, and those with high MELD scores (p \< 0.05 each) ([Table II](#t2){ref-type="table"}).

TABLE IIClinical findings, arterial blood gas analysis and intrapulmonary vascular dilatation in hepatosplenic schistosomiasis (HSS) patients with and without hepatopulmonary syndrome (HPS) HPS (n = 42)Non-HPS (n = 79)p-valueAge (years), mean ± SD52.79 ± 13.2257.05 ± 10.250.055Gender, n (%)Male25 (60)43 (54) Female17 (40)36 (46)0.591Clinical findings   Liver disease, n (%)   HSS15 (36)42 (53) HSS with cirrhosis27 (64)37 (47)0.069Spider naevi, n (%)13 (31)11 (14)0.029Child-Pugh class, n (%)A23 (55)64 (81) B/C19 (45)15 (19)0.003MELD score, mean ± SD12.31 ± 3.6810.46 ± 3.220.007SpirometryFVC (% predicted)76.90 ± 10.9173.73 ± 14.100.173FEV~1~(% predicted)81.50 ± 10.8078.20 ± 13.990.153FEV~1~/ FVC0.87 ± 0.070.86 ± 0.060.956Arterial blood gas analysisPaO~2~, mean ± SD77.60 ± 9.7880.41 ± 11.350.177PaCO~2~, mean ± SD35.14 ± 3.9436.67 ± 4.060.052AaPO~2~ ^*\**^, mean ± SD28.14 ± 9.5123.42 ± 12.470.037IPVD^*\**^, n (%)42 (100)9 (11)\< 0.001[^3]

Regarding the spirometry parameters and arterial blood gas analysis parameters, there were no significant differences between the patients with and without HPS, with the exception of the AaPO~2~ value, which was higher in patients with HPS (p = 0.037) ([Table II](#t2){ref-type="table"}).

Regarding abdominal ultrasound parameters (Symmers' fibrosis pattern, longitudinal diameter of the spleen and transverse diameters of the portal and splenic veins) and endoscopy parameters (calibre of the oesophageal varices and the presence of portal hypertensive gastropathy), we observed no significant differences between patients with and without HPS ([Table III](#t3){ref-type="table"}).

TABLE IIIUltrasound and endoscopic findings in hepatosplenic schistosomiasis (HSS) patients with and without hepatopulmonary syndrome (HPS) HPS (n = 42)Non-HPS (n = 79)p-valueUltrasound findings   Symmers' Fibrosis Pattern, n (%)   D25 (60)34 (43) E/F17 (40)45 (57)0.086Spleen, longitudinal diameter^*\**^15.01 ± 2.2415.81 ± 2.570.093Portal vein, transverse diameter^*\**^1.17 ± 0.311.24 ± 0.310.301Splenic vein, transverse diameter^*\**^0.95 ± 0.270.97 ± 0.310.790Endoscopic findings   Esophageal varices, n (%)   Mild24 (57)45 (57) Medium/Large18 (43)34 (43)0.985Portal hypertensive gastropathy, n (%)36 (86)58 (73)0.128[^4]

DISCUSSION
==========

The main finding of this study was the high prevalence of HPS in patients with HSS, than in patient with non-cirrhotic portal hypertension and those with cirrhotic portal hypertension on liver transplant waiting lists, as that reported in other studies evaluating the same diagnostic arterial blood gas parameters ([@B8], [@B21], [@B17], [@B13]). The prevalence of HPS observed in the present study was also higher than that reported in a study that examined patients with chronic forms of infection by *S. mansoni* (10% HPS prevalence) without mentioning the presence of oesophageal varices ([@B14]).

Although non-cirrhotic portal hypertension is associated with the development of HPS ([@B25]), it remains unclear whether the presence of HPS correlates with the highest levels of portal hypertension. In our study, parameters such as large-calibre oesophageal varices, portal hypertension gastropathy, very advanced periportal fibrosis, a greater longitudinal diameter of the spleen, portal collaterals and dilatation of portal vessels, usually present in patients with higher levels of portal hypertension ([@B10], [@B1], [@B4], were not significantly more frequent in patients with HPS. In fact, we observed that the prevalence of HPS was significantly higher among patients with spider naevi and high Child-Pugh and MELD scores, parameters that indicate the most severe liver function impairment. Thus, it is interesting to note that the incidence of HPS was higher in patients with concomitant cirrhosis than in those with HSS but without cirrhosis (42% vs. 26%), although there was only a trend of statistical significance.

These findings may suggest that, for patients in the present study, impaired hepatic function had a greater influence than the possible higher levels of portal pressure, over the occurrence of HPS. It may also be that the ultrasound and endoscopy changes secondary to portal hypertension, used herein as indirect parameters of portal hypertension, were insufficient to demonstrate any difference between patients with and without HPS. Hence, because the portal pressure was not measured, this point remains unclarified, and therefore constitutes one of the limitations of this study. However, the measurement of the hepatic venous pressure gradient, a method used to obtain the portal pressure level in patients with cirrhosis, does not properly assess the pressure in the venous portal system in patients with HSS because these patients present pre-sinusoidal portal hypertension ([@B7], [@B22]).

Another interesting finding of the present study was that the AaPO~2~ value was also elevated in patients without HPS. The involvement of lung tissue has been reported in patients with schistosomiasis, which was also described in an experimental study involving mice chronically infected with *S. mansoni* ([@B9], [@B11]). It should be noted that although the involvement of lung tissue was not a focus of our study, this might have contributed to the widened AaPO~2~, irrespective of the presence of IPVD, resulting in an overestimation of the frequency of HPS.

In conclusion, the concomitant occurrence of hepatic cirrhosis with HSS may have influenced the finding of a higher frequency of HPS in this study. Given that HPS interferes negatively in the prognosis of patients with cirrhosis, its investigation could be performed during the routine care of patients with HSS and oesophageal varices, especially in those patients with concomitant cirrhosis. The diagnostic evaluation of HPS in patients with schistosomiasis may require further evaluation of the additional involvement of interstitial lung disease in these patients. Further studies assessing the prognostic significance of HPS in patients with schistosomiasis would be of great interest to clinical practice.
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